Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for 18 F-FDG-directed and combined positron emission tomography (PET) and computed to...
Main Authors: | Thomas, Eloise, Mathieu, Clélia, Moreno‐Gaona, Patricia, Mittelheisser, Vincent, Lux, François, Tillement, Olivier, Pivot, Xavier, Ghoroghchian, Paiman Peter, Detappe, Alexandre |
---|---|
Other Authors: | Koch Institute for Integrative Cancer Research at MIT |
Format: | Article |
Language: | English |
Published: |
Wiley
2022
|
Online Access: | https://hdl.handle.net/1721.1/141216 |
Similar Items
-
Naked-eye sensitive detection of nanoPET by pH-responsive colorimetric method based on dual-enzyme catalysis
by: Wenchao Zhan, et al.
Published: (2024-04-01) -
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
by: Virginia Liberini, et al.
Published: (2021-04-01) -
BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01) -
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01) -
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01)